Uso do hormônio do crescimento em adolescentes com distrofia muscular de Duchenne
USA – adolescentes com distrofia muscular de Duchenne em uso de corticóides apresentam retardo do crescimento. Neste estudo 39 adolescentes receberam por um ano o tratamento com hormônio do crescimento. Houve um significativo aumento do crescimento neste tratamento. Não houve alteração do peso, da força muscular e da função cardíaca e respiratória. Não ocorreram efeitos colaterais.
O resumo em inglês pode ser lido abaixo:
(Neuromuscular Disorders, 2012) Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure
Meilan M. Rutter, James Collins, Susan R. Rose, Jessica G. Woo, Heidi Sucharew, Hemant Sawnani, Kan N. Hor, Linda H. Cripe, Brenda L. Wong – USA
This study evaluated efficacy and safety of growth hormone treatment in Duchenne muscular dystrophy boys with glucocorticoid-induced growth failure. We reviewed 39 consecutive boys (average age 11.5 years; 32 ambulatory) treated with growth hormone for 1 year during a four-year period. Boys were on long-term daily deflazacort or prednisone (mean duration 5 ± 2.2 years; dosing regimen prednisone 0.75 mg/kg/day equivalent). Primary outcomes were growth velocity and height-for-age z-scores (height SD) at 1 year. Height velocity increased from 1.3 ± 0.2 to 5.2 ± 0.4 cm/year on growth hormone (p < 0.0001). Pre-growth hormone decline in height SD (−0.5 ± 0.2 SD/year) stabilized at height SD −2.9 ± 0.2 on growth hormone (p < 0.0001). The rate of weight gain was unchanged, at 2.8 ± 0.6 kg/year pre-growth hormone and 2.6 ± 0.7 kg/year at 1 year. Motor function decline was similar pre-growth hormone and at 1 year. Cardiopulmonary function was unchanged. Three experienced side effects. In this first comprehensive report of growth hormone in Duchenne muscular dystrophy, growth hormone improved growth at 1 year, without detrimental effects observed on neuromuscular and cardiopulmonary function.
